top of page

Six Dragonfly-developed drugs are in clinical trials now, with our lead drug in Phase 2.  Four more Dragonfly-developed drugs are expected in the clinic by the end of 2023.

DRAGONFLY invents novel therapies that harness the body’s immune system, for vastly improved Patient Outcomes.

In collaboration with AbbVie, BMS, Gilead and Merck, our novel TriNKET™ and CYTOKINE platforms have generated 10 Drug Candidates that have been handed off to partners.

Activating the Immune
System to Fight Disease

Dragonfly-Sixth TriNKET Opt-in by BMS (Jan 2023)


Rights Revert back to Dragonfly for DF6002  (Feb 2023)


Dr. Joseph E. Eid joins Dragonfly (Feb 2023)


Latest News

Gilead’s team, now guided by R&D chief Flavius Martin, gets worldwide rights to DF7001, Dragonfly’s 5T4-targeting therapy designed to drag natural killer — NK cells — along with other cancer killing T cells into the tumor microenvironment.. [ENDPOINTS NEWS]

Our Collaborations

DRAGONFLY is a distinctively effective pharma partner.

Dragonfly rapidly develops drugs with our pharma partners, in expanding fields from oncology, to immunology, neuromuscular disease, virology, and beyond.


Our Platform


Tri-Specific NK cell Engager Therapy


Proprietary long-half-life cytokines

Two Proprietary Platforms

DRAGONFLY is a clinical-stage biotech that has developed a deep portfolio of drugs built on two unique platforms: first-in-class tri-specific NK engagers (“TriNKETs”)
and best-in-class CYTOKINEs – each with lead
drugs in the clinic with encouraging results. 

Growing the
Pipeline for Patients

In addition to a set of advanced programs in the clinic or handed off to our pharma partners, DRAGONFLY is developing 16+ TriNKETs and multiple CYTOKINES across a broad range of fields, including autoimmune and inflammatory diseases, fibrosis, neurology, infectious disease, and oncology.


DRAGONFLY's pipeline is rapidly growing in a number of
therapeutic areas of critical patient need.

bottom of page